Post by Biomed Industries Inc

Biomed Industries Advances NA-931 Into Two Global Phase 3 Trials Alone and with Semaglutide and Tirzepatide for Obesity Biomed announced today plans to initiate two global Phase 3 clinical programs evaluating NA-931 (120 mg orally once daily) as monotherapy and in combination with established GLP-1–based therapies semaglutide and tirzepatide for the treatment of obesity. NA-931 is a first-in-class, orally administered small-molecule quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors, designed to address obesity through integrated neuroendocrine and metabolic mechanisms. Read more at: https://lnkd.in/gEW9j2qT #NA931 #semaglutide #tirzepatide